Stock LUN LUNDBECK
Add to a list
To use this feature you must be a member
Log inSign up

Lundbeck Stock Nasdaq Copenhagen

Equities

LUN

DK0061804697

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:37 2024-05-08 am EDT 		5-day change 1st Jan Change
29.5 DKK +0.34% Intraday chart for Lundbeck +2.08% -14.59%
Apr. 09 H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Apr. 09 Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 20.99B 3.03B Sales 2025 * 21.83B 3.15B Capitalization 33.29B 4.81B
Net income 2024 * 3B 433M Net income 2025 * 3.42B 494M EV / Sales 2024 * 1.36 x
Net cash position 2024 * 4.66B 672M Net cash position 2025 * 8.37B 1.21B EV / Sales 2025 * 1.14 x
P/E ratio 2024 *
11.4 x
P/E ratio 2025 *
9.99 x
Employees 5,681
Yield 2024 *
2.57%
Yield 2025 *
2.94%
Free-Float 30.74%
More Fundamentals * Assessed data

Chart Lundbeck

Dynamic Chart

Latest news about Lundbeck

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia CI
H. Lundbeck A/S Announces Management Appointments CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023 CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug MT
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage CI
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023 CI
H. Lundbeck A/S Announces Changes to Executive Management CI
Nordic Shares Dropped Tuesday; Lundin Gold Posted Biggest Loss DJ
Transcript : H. Lundbeck A/S, 2023 Earnings Call, Feb 07, 2024
Transcript : H. Lundbeck A/S - Special Call
Transcript : H. Lundbeck A/S - Special Call
More news

Latest transcript on Lundbeck

Logo Lundbeck
H. Lundbeck A/S - Shareholder/Analyst Call
More transcripts

Press releases Lundbeck

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD AQ
Lundbeck : Articles of Association PU
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia AQ
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office AQ
Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage AQ
More press releases

Quotes and Performance

1 day+0.34%
Current month-14.59%
Current year-14.59%
More quotes

Highs and lows

3 years
28.52
Extreme 28.52
41.46
5 years
28.52
Extreme 28.52
61.70
10 years
22.30
Extreme 22.3
95.54
More quotes

Quotes

Date Price Change Volume
24-05-08 29.5 +0.34% 65,960
24-05-07 29.4 +1.38% 41,749
24-05-06 29 +0.87% 38,144
24-05-03 28.75 -0.17% 60,251
24-05-02 28.8 -0.35% 56,631

Delayed Quote Nasdaq Copenhagen, May 08, 2024 at 10:59 am EDT

More quotes

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
Pharmaceuticals
Calendar
2024-05-14 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Lundbeck

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
34.58 DKK
Average target price
38.71 DKK
Spread / Average Target
+11.94%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+20.94% 72.78B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.26% 24.24B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.13% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+8.25% 8.38B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-19.42% 8.09B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+16.83% 4.32B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.83% 4.05B
GALENICA AG Stock Galenica AG
-1.65% 3.93B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+26.97% 3.79B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. LUN Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW